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Abstract
Background. Patients facing a high-stakes clinical decision are often confronted with an overwhelming array of
options. High-quality decisions about treatment should reflect patients’ preferences as well as their clinical character-
istics. Preference-assessment instruments typically focus on pre-selected clinical outcomes and attributes chosen by
the investigator. Objective. We sought to develop a patient-centered approach to elicit and compare the treatment
goals of patients with multiple sclerosis (MS) and healthcare providers (HCPs).Methods.We conducted five nominal
group technique (NGT) meetings to elicit and prioritize treatment goals from patients and HCPs. Five to nine parti-
cipants in each group responded silently to one question about their treatment goals. Responses were shared, conso-
lidated, and ranked to develop a prioritized list for each group. The ranked lists were combined. Goals were rated
and sorted into categories. Multidimensional scaling and hierarchical cluster analysis were used to derive a visual
representation, or cognitive map, of the data and to identify conceptual clusters, reflecting how frequently items were
sorted into the same category. Results. Five NGT groups yielded 34 unique patient-generated treatment goals and 31
unique HCP-generated goals. There were differences between patients and HCPs in the goals generated and how
they were clustered. Patients’ goals tended to focus on the impact of specific symptoms on their day-to-day lives,
whereas providers’ goals focused on slowing down the course of disease progression. Conclusions. Differences
between the treatment goals of patients and HCPs underscore the limitations of using HCP- or investigator-identified
goals. This new adaptation of cognitive mapping is a patient-centered approach that can be used to generate and
organize the outcomes and attributes for values clarification exercises while minimizing investigator bias and maxi-
mizing relevance to patients.
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Understanding what matters to patients is critical in
high-stakes clinical decisions. Treatment decisions can
influence many aspects of a patient’s life beyond their
clinical symptoms, including independence, emotional
state, social interactions, and finances. While there is
growing consensus that patients’ values should be
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incorporated into clinical decisions,1,2 there is little con-
sensus on how this should be done.3 Simply asking
patients what they value is problematic, as people often
do not have pre-formed ideas about what is important to
them when confronted with complex or unfamiliar situa-
tions.4–6 Additionally, patients often have difficulty
applying deeply held values to health decisions.7
Values clarification exercises (VCE) aim to help
patients determine what matters most to them when
making a health decision.3,8 They are recommended
components of patient decision aids (DAs) and can help
patients choose treatments that are consistent with their
values.3,9 The most common approach to values clarifi-
cation is listing the pros and cons of options.10 Other
approaches include focused comparisons of the attri-
butes of treatments and the outcomes affected, using
mathematical models to assign weights to items (e.g.,
utility theory or stated preference approaches such as
conjoint analysis,11 best-worst-scaling, and discrete
choice12).
While much attention has been given to the mathe-
matical models for assigning weights to a set of attributes
and outcomes, less attention has been given to how those
attributes and outcomes are selected. It is established that
an individual’s values and preferences can be influenced,
or even formed, by the way they are elicited; even small
differences in rating procedures matter.13,14 Yet changing
the attributes and outcomes discussed can shift the focus
and trigger emotions, influencing how those outcomes
are perceived and valued.15
The task of selecting and organizing the attributes and
outcomes to include in a VCE is most often entrusted to
the developer or to expert physicians, often mirroring the
outcomes reported in clinical trials or guidelines16 or the
values deemed important by the developer. However,
clinical outcomes are often valued differently by patients
and physicians,17 and the inaccuracies of substituted
judgment, when surrogate decision makers make deci-
sions in lieu of the patient, have been well-documen-
ted.18,19 Thus, studies that ask patients to rate the wrong
set of outcomes lack external validity.20–22
Focus groups and/or interviews are sometimes con-
ducted to understand what matters to patients. However,
extracting and prioritizing patient preferences from these
discussions is difficult, subjective, and influenced by the
investigator’s own perspectives.23 Furthermore, interact-
ing groups can inhibit creative thinking by pursuing a
single train of thought for a long period, promoting pre-
mature evaluation, and inhibiting the participation of
more passive members. In contrast, the nominal group
technique (NGT) minimizes investigator bias, avoids
focusing on a single train of thought, prompts partici-
pants to generate their own issues, captures the specific
language of participants, maintains the autonomy of
individual viewpoints, allows equal input by each partici-
pant, and objectively prioritizes findings.24–26 Card sort-
ing exercises can capture how participants themselves
organize ideas generated in an NGT, further minimizing
investigator bias. Analyzing card sorting results using
multidimensional scaling (MDS)27–29 and hierarchical
cluster analysis (HCA)30 can produce a visual ‘‘cognitive
map’’ that facilitates obtaining input from stakeholders
who lack statistical expertise.31 This combination of
NGT coupled with card sort exercises and MDS and
HCA, referred to as ‘‘cognitive mapping,’’ has been
applied in many areas, but not yet to inform the attri-
butes included in VCE or DAs.
Our clinical focus is multiple sclerosis (MS), an
immune-mediated disease of the central nervous sys-
tem.32 Choosing the best treatment for patients with MS
has become more challenging because of the increasing
number of disease-modifying treatments available (14 in
2017).33 These treatments may differ in their effective-
ness, side-effects, risks, costs, and method of administra-
tion. A search of the literature identified 5 studies and 1
DA that addressed MS treatment preferences,34–39 each
using a different set of attributes and all but one38 using
investigator-selected attributes without specifying the
selection process.
Our objective was to develop a patient-centered
approach to identify the outcomes and attributes impor-
tant to patients making a high-stakes medical decision
regarding their MS. We sought to adapt cognitive
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mapping to compare the treatment goals of patients with
MS to those of experienced MS healthcare providers
(HCPs).
Methods
Sample
We included non-pregnant, English-speaking patients
with any type of MS between the ages of 21 and 75 years,
reflecting the epidemiology of MS.40
All patient participants were identified through
patient and HCP advisers with access to MS networks,
using a purposive sampling design. To enhance the inclu-
sion of disabled persons and increase geographic and
racial diversity, we offered both online and in-person
activities. In-person activities were conducted in
handicap-accessible facilities in Denver and Colorado
Springs, CO, Atlanta, GA, and Worcester, MA. Patient
recruitment targeted diversity in age, duration of MS,
race/ethnicity, education, and gender.
Our HCPs included neurologists, nurse practitioners,
physician assistants, or registered nurses who manage 10
or more MS patients a month, using a combination of
convenience and purposive sampling designs. HCP
recruitment targeted diversity in gender, years of train-
ing, and type of provider.
Recruitment used snowball sampling through strategi-
cally placed ads, flyers, and invitations. Recruitment
channels included MS support groups, educational
events, professional organizations, health blogs, and pri-
vate Facebook groups. Participants were invited to par-
ticipate between April 2015 and February 2016.
Informed consent was obtained online or in-person
for each study activity. This study was approved by the
New England Independent Review Board.
Study Procedures
We used a multi-step cognitive mapping approach in
which NGT meetings were used to elicit and prioritize
treatment goals from patients and HCPs. A subsequent
card sorting exercise, involving a larger sample, rated
and clustered the prioritized goals. MDS and HCA were
used to analyze card sort responses. NGT participants
could elect to participate in subsequent card sorting
activities.
Five to nine participants were assigned to each NGT
group. Groups were led by an experienced moderator
(NFC) and co-led by a locally respected peer. To stan-
dardize meetings across sites, instructions were provided
through a series of instructional videos. Participants were
asked to silently respond to one carefully worded ques-
tion (pre-tested in cognitive interviews), writing down as
many brief responses as they wished. Patients were asked
‘‘What do you specifically hope to achieve (or avoid),
now and in the future, when you choose ways to manage
your MS?’’ HCPs were asked: ‘‘What do you hope to
achieve or avoid when you manage your patient’s MS?’’
Participants requiring assistance were paired with an
assistant. Participants could submit sensitive topics
anonymously. Next, in a round-robin, each subject read
aloud one of their responses until all unique responses
were recorded on a shared list. The moderator read any
anonymous topics. Each item on the list was reviewed by
the group for clarity and redundancy. Finally, partici-
pants were asked to silently identify and rank the 9 most
important items (the maximum number that can be
effectively ranked).41
We developed a 2-step online NGT protocol that mir-
rored the in-person protocol. Participants could respond
when and where they chose (asynchronously), spend as
much time as needed, and complete the activity over
multiple sessions. Instructional videos (identical to those
shown during the in-person meetings) explained proce-
dures. In step one, participants viewed the videos, read
the NGT question, and submitted their responses. After
all participants’ responses were submitted, the responses
were consolidated independently by 2 facilitators (NFC,
VS), involving another advisor to resolve any differences.
In step two, 1 to 3 weeks later, participants were shown
the consolidated list, asked if they agreed with the way
items were combined and how they would like to change
it. They were then asked to rate each item for clarity (‘‘Is
this concept clear?’’, ‘‘How would you suggest it be
improved?’’) and redundancy (Is the item unique? If not,
‘‘which other item(s) should it be combined with?’’), and
then asked to rank the top 9 items.
After completing all NGTs (in-person and online), 2
consolidated lists of treatment goals were generated (1
for patients, 1 for HCPs) by carrying forward all priori-
tized items (receiving at least 1 point), combining items
that conveyed the same meaning, and removing or
rewording confusing items. MS patient and HCP advis-
ers (BT, AH, MM, LQ, CG, AS) guided this process.
We attempted to combine patient and HCP prioritized
responses onto a single list, but many of the HCP items
were unclear to patients.
The consolidated list of patient treatment goals was
used for rating and card sorting among both patients and
HCPs. Participants rated the importance of each goal by
indicating the strength of their agreement or disagree-
ment with each one, using a 5- or 10-point Likert scale
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(online v. in-person, respectively). Participants were then
asked to use their own criteria (e.g., ‘‘how you see these
items going together?’’) to sort the 34 items into 3 to 10
groups containing any number of perceptually similar
cards.42 This was done either in-person using a shuffled
deck of cards, or online, using customized Qualtrics soft-
ware. Online participants were asked to label each group.
Data Analyses
Within each NGT meeting, weights were assigned to
each ranked item (i.e., 9 points for the 1st, 1 point for the
9th) and scores from each participant were summed to
develop an aggregated, prioritized list. Ratings con-
ducted during the card sorting exercises were calculated
using the mean and SD, and rescaled to a 10-point scale.
Results of all of the online and in-person activities
appeared similar and were combined (the online
Appendix compares online and in-person findings).
Using customized software, the card sort data were
transformed into a 34 3 34 co-occurrence matrix that
recorded how often 2 items were sorted into the same
group. MDS (‘‘PROXCAL’’ software algorithm) was
applied to the group co-occurrence matrix using Euclidean
(i.e., straight-line) distances. MDS creates a visual ‘‘cogni-
tive map’’ of the spatial relationships between the attri-
butes that approximates the perceived similarity of items.
The more often items were sorted into the same group, the
closer they appeared in the diagram. The space can be
multi-dimensional, but only 2-dimension solutions are
interpretable. Goodness-of-fit is determined by the stress
statistic (below 0.15 corresponds to a good fit).43,44
HCA (using Ward’s Linkage) was used to draw
boundaries around groups of goals, demarcating concep-
tual clusters of related goals. A cluster tree (dendrogram)
represents the distance between the clusters by the length
of the branches. It illustrates potential clusters but not
the actual number of clusters. Final clusters conformed
to the dendrogram, using patient input to identify and
label the most meaningful clusters (Appendix Figures
2A, 3A, and 4A). MDS and HCA are robust to viola-
tions of their assumptions. All analyses were performed
using SPSS Statistics 23.
Results
Seventy-one participants took part in the study (47
patients, 24 HCPs; Figure 1). Our patient sample (Table
1) appears representative, as it resembles another repre-
sentative study’s sample.45 Our HCPs had an average of
10.5 years in practice (range, 1 to 32), 71% were female,
and 42% were physicians (neurologists), 33% physician
assistants, and 25% nurses or nurse practitioners. Forty-
six percent of the HCPs who participated in the NGT
meetings were affiliated with a MS Center, 31% reported
seeing over 50 patients with MS each month, 62%
between 11 and 50 patients, the remainder seeing approx-
imately 10 patients/month.
Treatment Goals Generated by Patients and
HCPs
All subjects who consented completed the NGT activities.
Three patient NGT meetings (2 in-person, 1 online) gen-
erated 34 unique goals; 2 in-person HCP NGT meetings
generated 31 unique goals. Many of the patient goals were
not mentioned by HCPs and vice versa; in addition, dif-
ferences in terminology were observed (Table 2). Among
patients, maintaining bladder and bowel function was the
most important symptom management goal, much more
than managing pain. In contrast, HCPs endorsed pain
more strongly than bladder and bowel function.
Ratings of Patient Treatment Goals
All subjects who consented to the card sorting exercise
completed all ratings. Both HCPs and patients strongly
Table 1 Patient Characteristics (n= 47)
n (%)
Age in years, average (SD) 52 (12)
Gender
Male 9 (19.2%)
Female 38 (80.8%)
Race
White/Caucasian 87.2%
Black/African American 12.8%
Type of MS
Relapsing Remitting MS 40 (85.1%)
Primary Progressive MS 4 (8.5%)
Secondary Progressive MS 2 (4.3%)
Not reported 1 (2.1%)
Time since diagnosis in years,
mean (SD)
12.41 (9.4)
Patient Determined Disease Steps
score,46 mean (SD)
3.54 (2.1)a
Past or current DMTb use 92.31%
Educational level
High school graduate/GED 2 (4.3%)
Some college 11 (23.4%)
2-year college/technical school 5 (10.6%)
College graduate 17 (36.2%)
Graduate school or professional degree 12 (25.5%)
aExcludes participants in the in-person card sort group
bDMT, disease modifying treatment
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endorsed most of the goals, HCPs more so than patients
(mean ratings of 9.49 (0.58) and 8.83 (1.32), respectively;
P \ 0.05). ‘‘Avoiding medicines with fatal side effects’’
was the most endorsed goal for patients but one of the
least endorsed goals for HCPs (Figure 2). The goals most
similarly rated by patients and HCPs were ‘‘Maintain or
improve memory,’’ ‘‘Prevent brain atrophy,’’ and ‘‘Stay
relatively healthy.’’ Those with the greatest differences
were ‘‘Avoid assistive devices,’’ ‘‘Stay working,’’
‘‘Decrease pain,’’ and ‘‘Help with symptoms of depres-
sion,’’ which were more strongly endorsed by HCPs than
patients.
Cognitive Mapping
All but one person who consented to the card sorting
activity completed the sorting (100% for the online sam-
ple, 95.8% for the in-person sample). The 2-dimensional
solutions for the MDS analyses indicated robust
goodness-of-fit measures for the patient, HCP, and com-
bined models (stress = 0.0426, 0.0133, and 0.0319,
respectively). Nine patient clusters and 8 HCP clusters
were derived from the 34 patient treatment goals
(Figures 3, 4; Tables 3, 4; Appendix Figure 4A). Our
cluster analyses revealed areas of overlap between clus-
ters; yet, none of the clusters were identical across the 2
cohorts. Among patients, the most important cluster was
‘‘Brain health,’’ followed by ‘‘Disability concerns.’’
We interpreted one dimension of the patients’ cogni-
tive map as ranging from factors internal to the patient
to external to the patient; the other dimension, ranging
from physical to psychosocial impact. We interpreted
one dimension of the HCPs’ cognitive map as factors
internal v. external to the patient; the other dimension,
ranging from biological to social impact.
Discussion
We were able to adapt cognitive mapping techniques to
identify and prioritize patient treatment goals and com-
pare them to HCP goals. Our approach elicited a broad
spectrum of goals directly from patient and HCP stake-
holders and organized them into meaningful clusters
with minimal investigator input. Many of the domains
identified have not been previously reported, including
‘‘Brain health,’’ ‘‘Daily living and lifestyle expectations,’’
‘‘Disability concerns,’’ ‘‘Preventative measures,’’ and
‘‘Medical team.’’ We also identified many specific prefer-
ence attributes for MS that have not been previously
identified, including prevent brain atrophy; avoid loss of
strength; have a doctor who is very aware, knowledge-
able, and compassionate; better balance; overcome fati-
gue; lessen heat sensitivity; be independent; maintain a
normal sex life; stay working; avoid hospital admissions;
avoid assistive devices; and age in place. Our identifica-
tion of new domains could reflect the success of our
Figure 1 Study design and sample.
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methods or that few previous studies have asked patients
themselves.
We found some differences between the treatment
goals generated by patients and HCPs. Goals generated
by patients more often involved improving specific day-
to-day symptoms, whereas those generated by HCPs
involved slowing disease progression. HCP goals
appeared to reflect, in part, outcomes that they perceived
they could influence with the medical interventions at
their disposal. Improving conditions that were beyond
their sphere of influence (e.g., heat sensitivity) were not
offered by HCPs and also received lower endorsement
ratings. HCPs’ stronger endorsement of pain may reflect
the influence of the ‘Pain as the Fifth Vital Sign’ initia-
tive.47 However, because of the limited variation in HCP
and patient ratings, we have less confidence in those
findings.
Differences between how patients and HCP cohorts
clustered treatment goals may reflect differing under-
standings of underlying disease processes. For example,
HCPs grouped cognition and memory as symptoms
along with bladder and bowel function, whereas patients
grouped cognition and memory in a separate category
along with brain atrophy.
HCPs used global constructs (e.g., quality of life)
more frequently than did patients. Some of those global
constructs could be loosely interpreted as encompassing
many of the specific items that patients listed as distinct
goals. However, relating the HCPs’ broad goals to the
patient’s specific goals was impeded by differences in ter-
minology and differences in the semantic meaning
attached to the terms. Confusion about terms used to
describe the clinical course of MS has been a recurring
theme in the scientific literature on MS,48,49 with the
meaning of terms such as ‘‘disability’’ and ‘‘progression’’
changing as the definitions of MS have evolved.
Clinically, progression implies ‘‘progression of clinical
disability,’’ reflected in HCPs’ grouping of ‘‘Avoiding
further disability’’ with ‘‘Avoid or slow progression of
MS,’’ ‘‘Avoid flare-ups,’’ and ‘‘Preventing brain atro-
phy’’. In contrast, patients grouped ‘‘Avoiding further
disability’’ with ‘‘Losing ability to walk,’’ ‘‘Loss of full or
partial body strength,’’ and ‘‘Losing vision,’’ consistent
with the lay definition of disability (conditions that limit
a person’s movements). These differences underscore the
potential problems with using HCP-identified instead of
patient-identified goals. Moreover, because many of the
terms used by patients convey a different meaning to
HCPs, simply asking patients to share their goals with
their HCP may not suffice to bridge communication
gaps. To support shared decision making, patient goals
may need to be explained to HCPs in different terms.
As the number of treatment choices for chronic dis-
eases increases and the spectrum of clinical, functional,
and economic outcomes affected by treatments increase,
so do the challenges of selecting the best outcomes and
attributes for inclusion in VCE and DAs. Guidance for
developing DAs concluded that there is no consensus on
how to select material for inclusion in DAs, recommend-
ing ‘‘needs assessment via focus groups and literature
review, and direct observations of clinical interactions
during office visits.’’50 Yet those traditional approaches
Table 2 Top Ten Ranked Treatment Goals, Patient-Reported V. HCP-Reported (from 3 NGTs)a
Rank Patient-Reported Goals HCP-Reported Goals
1 Avoid medicines with fatal side-effects Avoid or prevent disability (physical, cognitive, function)
2 Maintain or improve memory Prescribe effective medications (to control the disease process)
3 Prevent brain atrophy Improve patient’s quality of life
4 Have a doctor who’s aware,
knowledgeable, and compassionate
Effectively manage symptoms associated with MS
5 Avoid losing ability to walk Make sure there is unbiased patient education about
MS (pathophysiology), importance of treatments, risks
and benefits of each option
6 Maintain good cognitive ability Minimize risks to the patient (do no harm)
7 To stay relatively healthy Build a good patient-physician relationship—communication/
Build trust in patient-provider relationship
8 Avoid losing vision Support the emotion distress of the disease burden/Address the
mental health aspects of their disease
9 Avoid loss of full or partial body strength Create a sense of mental control of the patient against their disease
10 Stay as active as possible (e.g., exercise) Keeping updated on new treatments and side-effects
aResponses include the original wording of items.
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are themselves prone to investigator bias.24 Further, rely-
ing on a literature review can propagate errors if those
published studies did not involve patients. A systematic
review of patient priorities for practice care reported that
25% of the published studies included items that were
‘‘invented by the researchers,’’ 44% were ‘‘unclear,’’ and
23% were sourced from other literature.51 VCE that do
not include the attributes that matter to the decision
maker will produce unreliable results. No amount of
finesse or mathematical sophistication in comparing
items can compensate for choosing the wrong set of out-
comes. There is a pressing need to both standardize and
increase the transparency of the process used to select
the outcomes and attributes included in DAs and VCE.
This approach addresses the issue of how to select attri-
butes, by minimizing the influence of the researcher and
allowing selections to be made by the patients.
Our study had several limitations. Comparisons of
patients with HCPs was hindered by a small HCP sam-
ple. However, because MDS and HCA are not based on
parametric statistics, their validity is not dependent on
the size of the sample but rather on the representative-
ness of the participants.47 Differences in treatment goals
might be expected because HCPs were asked about their
treatment goals, not patients’. However, because expert
physician opinion is commonly used to identify attri-
butes, this seemed the most meaningful approach. HCPs
highly endorsed all goals, rendering differences in
Figure 2 Ratings of patients’ treatment goals. Patients v. HCPs (ranked according to differences in rating).
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importance ratings less meaningful. We combined find-
ings from online and in-person activities, recognizing
that the method of collecting responses likely had some
influence on those responses. The labels assigned to the
dimensions identified by MDS are speculative, as are our
interpretations of differences between groups.52 This
method minimizes researcher bias but does not eliminate
it. Judgment and investigator input were needed to com-
bine lists across NGTs, select the number of clusters, and
interpret findings. Our protocol minimized these influ-
ences by involving non-HCP and patient advisers in all
steps.
The disadvantages of traditional NGT meetings
include constrained time for responding, variations in
the protocol across groups, and the suppression of sensi-
tive topics (due to round-robin reporting). The adapta-
tions developed for this study minimize those challenges
by including a protocol for the anonymous submission
Table 3 Patient Treatment Goals, Clustered with Patient Ratings
Treatment Goals Mean Rating SD
Cluster 1 Brain health (memory, thinking, brain) 9.41 0.01
Maintain or improve memory 9.41 0.97
Prevent brain atrophy 9.41 0.97
Maintain good cognitive ability 9.39 1.00
Cluster 2 Disability concerns (walking, strength, vision) 9.28 0.06
Avoid losing ability to walk 9.41 1.18
Avoid losing vision 9.32 1.27
Avoid loss of full or partial body strength 9.26 1.14
Avoid further disability 9.15 1.30
Cluster 3 Avoid flare-ups or progression 9.04 0.19
Avoid or slow progression of MS 9.20 1.57
Avoid flare-ups 8.88 1.19
Cluster 4 Caring and knowledgeable medical team 9.02 0.25
Have a doctor who is very aware, knowledgeable, and compassionate about MS 9.41 1.07
Have choices in medicine that address quality of life issues not just progression 9.05 1.20
Find a treatment that works better (that is more effective) 8.59 1.66
Cluster 5 Safe treatments 8.95 0.24
Avoid medicines with fatal side-effects 9.44 1.14
Avoid compromising my quality of life with medication side effects 8.46 1.63
Cluster 6 Symptom management (including fatigue, bladder issues, heat sensitivity, pain, balance) 8.83 0.15
Maintain bladder and bowel function 9.12 1.05
Have better balance (for example, be able to balance without falling) 8.68 1.40
Overcome fatigue 8.68 1.33
Decrease pain 8.32 1.49
Find ways to help with symptoms of depression 8.17 1.32
Find ways to lessen heat sensitivity 7.88 1.55
Cluster 7 Daily living and lifestyle expectations 8.74 0.30
To stay relatively healthy 9.38 0.85
Stay as active as possible, for example, exercise 9.25 0.93
To be able to age in place and not have to go to a care facility 9.17 1.38
Be independent 9.02 1.23
Be able to take care of my family 8.41 1.61
Stay working as long as possible 8.27 1.76
A lifestyle schedule that I can adapt to 8.22 1.31
Maintain a normal sex life 8.22 1.59
Cluster 8 Financial Concerns (affordable treatments, financial independence) 8.72 0.09
Be able to afford necessary treatments 9.20 1.19
Be financially independent 8.71 1.40
Affordable complementary choices (for example, chiropractor, Physical Therapy) 8.27 1.36
Cluster 9 Preventative measures (avoiding hospitalizations assistive devices) 8.29 0.12
Avoid hospital admissions 8.61 1.55
Avoid having to modify home to meet physical needs 8.22 1.46
Avoid assistive devices (for example, wheelchairs, walkers) 8.05 1.75
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of topics, videos that standardize the protocol across
groups, and asynchronous online activities that support
more inclusive sampling and thoughtful responses by
removing time limits.
Tailoring discussions about treatments to reflect out-
comes of importance to the decision maker is essential to
shared decision making.53,54 But the critical and often
missing first step is identifying those outcomes. The
patient-centered cognitive mapping approach described
in this manuscript could be used to improve the validity
of VCE and stated preference methods by improving the
process for selecting the attributes that they include,
increasing the transparency of the attribute development
process and resulting in a more appropriate set of attri-
butes. This approach could also be used to guide the
content of DAs, tailor behavioral change interventions,
and improve patient–provider communication. Knowing
what matters to a patient could assist HCPs in under-
standing their patients, help build more trusting relation-
ships, identify treatments that are a better fit for that
Table 4 HCP Clusters and HCP ratings of Patient Treatment Goals
Treatment Goals HCP rating SD
Cluster 1 Disease process 9.76 0.41
Avoid or slow progression of MS 9.91 0.28
Avoid further disability 9.87 0.34
Avoid flare-ups 9.70 0.46
Prevent brain atrophy 9.57 0.58
Cluster 2 Mobility issues 9.72 0.42
Avoid loss of full or partial body strength 9.83 0.38
Avoid losing ability to walk 9.83 0.38
Avoid losing vision 9.78 0.41
Have better balance (for example, be able to balance without falling) 9.43 0.50
Cluster 3 Activity 9.61 0.55
Stay as active as possible, for example, exercise 9.74 0.44
Avoid hospital admissions 9.65 0.48
To stay relatively healthy 9.57 0.58
Avoid assistive devices (for example, wheelchairs, walkers) 9.48 0.71
Cluster 4 Disease modifying treatment (DMT) issues 9.50 0.68
Have a doctor who is very aware, knowledgeable, and compassionate about MS 9.78 0.41
Have choices in medicine that address quality of life issues not just progression 9.65 0.48
Find a treatment that works better (that is more effective) 9.61 0.64
Avoid compromising my quality of life with medication side effects 9.57 0.58
Avoid medicines with fatal side-effects 8.91 1.28
Cluster 5 Independence/ Quality of life 9.39 0.64
Be independent 9.65 0.70
Stay working as long as possible 9.65 0.56
To be able to age in place and not have to go to a care facility 9.52 0.58
Be able to take care of my family 9.52 0.50
Be financially independent 9.39 0.64
A lifestyle schedule that I can adapt to 9.09 0.78
Avoid having to modify home to meet physical needs 8.87 0.74
Cluster 6 Financial issues 9.37 0.56
Be able to afford necessary treatments 9.65 0.48
Affordable complementary choices (for example, chiropractor, Physical Therapy) 9.09 0.65
Cluster 7 Symptom management 9.35 0.63
Maintain good cognitive ability 9.61 0.64
Maintain bladder and bowel function 9.43 0.58
Maintain or improve memory 9.30 0.69
Maintain a normal sex life 9.04 0.62
Cluster 8 Complex outcomes affected by MS 9.26 0.67
Decrease pain 9.61 0.49
Overcome fatigue 9.48 0.58
Find ways to help with symptoms of depression 9.39 0.64
Find ways to lessen heat sensitivity 8.57 0.97
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patient, and focus on the pros and cons of treatments that
are most important to the patient, thereby reducing infor-
mation overload and promoting patient engagement.
The NGT is beginning to be used to understand
patient preferences for MS treatments. The first study
using NGTs (combined with best–worst scaling) among
patients with MS was published in late 2016,55 focusing
on attributes of disease-modifying drugs.
The findings from this study have been used to
develop and validate a preference assessment tool to help
patients with MS explore and share their goals with their
HCP. (This is available at Available at https://tinyurl
.com/WhatMattersMS.) This tool is currently being
expanded into a shared decision making tool for MS and
will be evaluated in real-world settings. While we have
focused on MS treatment goals in this study, the
approach is applicable to other preference-sensitive clini-
cal decisions. Helping patients better understand their
treatment goals and making HCPs aware of their goals
should improve patient-provider communication and
promote shared decision making.
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